
NYSEHealthcareMedical - Devices
最新資料
US$366.16
+US$5.76 · +1.60%
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
前收盤價
US$366.16
+US$5.76 · +1.60%
盤中時間採用ET。市場資料可能有所延遲。
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
日內區間
目前US$366.16
52週區間
目前US$366.16
盤中時間採用ET。市場資料可能有所延遲。
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
日內區間
目前US$366.16
52週區間
目前US$366.16
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 25.83億 USD | 25.67億 USD | 26.71億 USD | 28.02億 USD | 29.23億 USD |
| 銷貨成本 | 12.4億 USD | 11.88億 USD | 12.44億 USD | 12.35億 USD | 12.84億 USD |
| 毛利 | 13.44億 USD | 13.79億 USD | 14.27億 USD | 15.67億 USD | 16.38億 USD |
| 研究與開發 | 2.57億 USD | 2.96億 USD | 2.47億 USD | 2.57億 USD | 2.61億 USD |
| 銷售、一般及管理費用 | 8.2億 USD | 8.14億 USD | 8.42億 USD | 8.28億 USD | 8.77億 USD |
| 營業費用 | 10.78億 USD | 11.1億 USD | 10.89億 USD | 10.85億 USD | 11.38億 USD |
| 利息收入 | 9550萬 USD | 8200萬 USD | 1.01億 USD | 5800萬 USD | 1890萬 USD |
| 利息支出 | 4900萬 USD | 4890萬 USD | 4943.9萬 USD | 3811.4萬 USD | 155.1萬 USD |
| 折舊和攤銷 | 1.65億 USD | 1.52億 USD | 1.46億 USD | 1.37億 USD | 1.38億 USD |
| 營業利益 | 2.71億 USD | 2.69億 USD | 3.38億 USD | 4.83億 USD | 5億 USD |
| 淨利 | 7.6億 USD | −18.44億 USD | −6.37億 USD | −36.28億 USD | 42.54億 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.26億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1.64億0.09%1853億 USD0.03%US$289.48+0.64%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1.48億0.55%268.09億 USD0.33%US$37.95-0.39%
Vanguard Morningstar Small-Cap Value ETFVBR1.04億0.15%682億 USD0.05%US$234.43+0.22%
Vanguard Extended Market ETFVXF8086.4萬0.08%954億 USD0.05%US$235+0.80%
Dimensional - US Small Cap ETFDFAS5290.85萬0.16%338.69億 USD0.31%US$78.35+0.32%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY4875.62萬0.19%258.17億 USD0.23%US$669.87+0.54%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD3511.81萬0.19%182.7億 USD0.03%US$64.33+0.56%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMDAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。